5.31
+0.2(+3.91%)
Currency In USD
| Previous Close | 5.11 |
| Open | 5.09 |
| Day High | 5.46 |
| Day Low | 5.01 |
| 52-Week High | 10.11 |
| 52-Week Low | 2.9 |
| Volume | 3.07M |
| Average Volume | 2.9M |
| Market Cap | 468.65M |
| PE | -4.96 |
| EPS | -1.07 |
| Moving Average 50 Days | 4.19 |
| Moving Average 200 Days | 4.71 |
| Change | 0.2 |
If you invested $1000 in Altimmune, Inc. (ALT) since IPO date, it would be worth $40.71 as of December 04, 2025 at a share price of $5.422. Whereas If you bought $1000 worth of Altimmune, Inc. (ALT) shares 5 years ago, it would be worth $439.76 as of December 04, 2025 at a share price of $5.422.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Altimmune Announces CEO Transition and Succession Plan
GlobeNewswire Inc.
Dec 01, 2025 12:30 PM GMT
Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2025 12:30 PM GMT
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
GlobeNewswire Inc.
Nov 11, 2025 1:51 PM GMT
24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile Significant improvements observed in secondary endpoints, including reductions in liver fat, in